Global Business
Novartis raises core profit outlook despite a sharp fall in reported earnings
Novartis improved its annual core operating profit forecast as priority medicines supported sales. Reported quarterly profit fell sharply, however, mainly because of an impairment linked to del-desiran. The results show a substantial difference between the company’s reported and adjusted performance.
এই খবরটি আপাতত ইংরেজিতে পড়ুন
From 28 October 2026 — Global Business & Tech
28 OCT 2026 · 4/25
Novartis raised its full-year core operating profit outlook after third-quarter sales increased, despite a sharp fall in reported earnings following a drug-asset impairment.
The Swiss pharmaceutical group said net sales rose 4%, both in dollars and at constant exchange rates. Growth in medicines including Kisqali, Kesimpta and Scemblix helped offset erosion from generic competition.
Core operating income increased 10% at constant currencies, and its core operating margin reached 41.6%. Novartis now expects annual core operating income to be broadly unchanged or grow by a low-single-digit percentage, replacing an earlier forecast for a low-single-digit decline. Its sales outlook was unchanged.
Reported operating income fell 59% in dollars and net income dropped 70%, mainly because of a partial impairment of the del-desiran asset. Those declines underline the difference between statutory results and the company’s core measures.
Quarterly free cash flow was $5.1 billion, down 18% in dollars.